Olubukola Ayodele, Breast Cancer Lead at University Hospitals of Leicester NHS Trust, shared a post on LinkedIn:
“What a week for the CONCISE team at SABCS25. I’m incredibly proud that not one but two of our subgroup analyses received major international awards: The Arti Hurria Award in geriatric oncology and the Male Breast Cancer Global Alliance Merit Award.
It’s essential to understand how adjuvant abemaciclib is used outside clinical trials, as this represents the true cohort of patient exposure.
Data was collected via the Ledidi platform, from 1,000+ patients treated in 21 NHS Trusts. Our primary analysis showed that abemaciclib is feasible in routine practice; however, dose reductions and early discontinuation were more common than reported in the MonarchE study.
Median treatment duration was 15.5 months, and toxicities followed the expected pattern, with diarrhoea, cytopenias and transaminitis being most frequent. These insights underscore the importance of supportive care and patient-centred management in ensuring people stay on therapy long enough to benefit.
Our analysis of older adults highlighted the nuances of treating patients aged 65 and above. Those over 75 had shorter treatment duration and higher discontinuation due to toxicity, despite similar adverse event profiles. It’s a reminder that age alone isn’t the issue; it’s fitness, comorbidities and the need for tailored assessments. This dataset is one of the largest of its kind in the UK and gives much-needed evidence to guide real-world decisions in geriatric oncology.
Although our male breast cancer cohort has small numbers, the findings shed light on outcomes in a group that has been largely invisible in prospective trials. Treatment was generally manageable, though discontinuation due to toxicity was higher than in the overall cohort, pointing to the need for dedicated research and supportive strategies for men with breast cancer.
To see the CONCISE study recognised twice on a global stage is encouraging. More importantly, these analyses help us understand how to deliver equitable, safe and effective care for groups who are often underrepresented in clinical trials. We will continue to follow up these patients and present the efficacy data when it becomes mature.
Grateful for every collaborator, every centre and every patient who made this possible.
Thank you to the Male Breast Cancer Global Alliance (Org Page), Cheri A., and the American Association for Cancer Research for supporting our work.”
More posts from SABCS 2025.
